[
  {
    "ts": null,
    "headline": "Sudo Biosciences Appoints Paul Bavier as Chief Legal Counsel",
    "summary": "CARMEL, Ind. & LONDON, December 04, 2025--Sudo Biosciences Appoints Paul Bavier as Chief Legal Counsel",
    "url": "https://finnhub.io/api/news?id=94557e1eec504e1060c9f2efa8391a90036913a2b3abd26620da93e43ec03c49",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764853200,
      "headline": "Sudo Biosciences Appoints Paul Bavier as Chief Legal Counsel",
      "id": 137680129,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "CARMEL, Ind. & LONDON, December 04, 2025--Sudo Biosciences Appoints Paul Bavier as Chief Legal Counsel",
      "url": "https://finnhub.io/api/news?id=94557e1eec504e1060c9f2efa8391a90036913a2b3abd26620da93e43ec03c49"
    }
  },
  {
    "ts": null,
    "headline": "Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy",
    "summary": "Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth potential. Click for this CRSP update.",
    "url": "https://finnhub.io/api/news?id=0c0fd8fef65b190bf9c8395f52f646fd5a20fb1ef943bb2877d45e24b9f1f0de",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764844190,
      "headline": "Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy",
      "id": 137680924,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2196575232/image_2196575232.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth potential. Click for this CRSP update.",
      "url": "https://finnhub.io/api/news?id=0c0fd8fef65b190bf9c8395f52f646fd5a20fb1ef943bb2877d45e24b9f1f0de"
    }
  },
  {
    "ts": null,
    "headline": "Alzheimer's Clinical Trial Results, Sadly Running True To Form",
    "summary": "There have been some interesting failures recently in Alzheimerâs trials. Two are notable because theyâre aimed outside the usual amyloid zone. Read more here...",
    "url": "https://finnhub.io/api/news?id=65052528a06cb144d6b694919c60a3c0211de516cc9fc309ceb4958d5ddb64c0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764829800,
      "headline": "Alzheimer's Clinical Trial Results, Sadly Running True To Form",
      "id": 137678942,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160716915/image_2160716915.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "There have been some interesting failures recently in Alzheimerâs trials. Two are notable because theyâre aimed outside the usual amyloid zone. Read more here...",
      "url": "https://finnhub.io/api/news?id=65052528a06cb144d6b694919c60a3c0211de516cc9fc309ceb4958d5ddb64c0"
    }
  }
]